Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Telmisartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Bausch Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
George Medicines, Bausch Health Sign Licensing Agreement for GMRx2 in Canada
Details : Under the terms of the licensing agreement, Bausch Health will hold the exclusive rights to commercialize, GMRx2 in Canada, Mexico etc. It is being evaluated for the treatment of hypertension.
Product Name : GMRx2
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 13, 2025
Lead Product(s) : Telmisartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Bausch Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Telmisartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
George Medicines Files NDA with FDA for Triple Combination Therapy for Hypertension
Details : GMRx2 is a triple combination of telmisartan, amlodipine and indapamide, in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhage.
Product Name : GMRx2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 08, 2024
Lead Product(s) : Telmisartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telmisartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GMRx2 is a single-pill, multi-mechanism, triple combination of telmisartan, amlodipine and indapamide, in novel and proprietary dosage strengths and is in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhag...
Product Name : GMRx2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 07, 2023
Lead Product(s) : Telmisartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metformin,Dapagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : CUREator
Deal Size : $1.0 million
Deal Type : Financing
Details : GMRx4 is being developed to provide a synergistic effect from three best-in-class type 2 diabetes treatments – metformin, dapagliflozin and sitagliptin – and, in an ultra-low-dose, single pill formulation, aims to be a more effective, simpler and saf...
Product Name : GMRx4
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 20, 2022
Lead Product(s) : Metformin,Dapagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : CUREator
Deal Size : $1.0 million
Deal Type : Financing
Lead Product(s) : Telmisartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GMRx2 is George Medicine’s most advanced candidate in late-stage development. A single-pill triple combination, it contains low doses of the commonly used hypertension medications telmisartan, amlodipine and indapamide.
Product Name : GMRx2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : Telmisartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telmisartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GMRx2 is a single pill triple combination in novel and proprietary dosage strengths containing telmisartan, amlodipine and indapamide, targeted for first line therapy to control hypertension.
Product Name : GMRx2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2021
Lead Product(s) : Telmisartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable